PTC Therapeutics (PTCT) P/S ratio

P/S ratio today
3.1×

PTC Therapeutics (PTCT) trades at 3.1× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 3.9×. That is 9.8% lower than the 4.3× of fiscal 2024. Figures as of 18 Nov 2026, 06:54 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
3.1×
P/S ratio, fiscal 2025
3.9×
Change on fiscal 2024
−9.8%
Highest on record
64.7×fiscal 2014
Lowest on record
2.2×fiscal 2023
Fiscal years on record
92013–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

PTC Therapeutics P/S ratio, in more detail

Today's figure is 20.5% below the fiscal 2025 year-end.

Across the 9 fiscal year-ends on record (2013–2025), the highest was 64.7× in fiscal 2014 and the lowest 2.2× in fiscal 2023. Today's P/S ratio is higher than at 11% of the 9 fiscal year-ends on record; their median is 5.2×.

History · 9 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

PTC Therapeutics P/S ratio, year by year

PTC Therapeutics (PTCT) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today3.1×—$60.36—
20253.9× 9.8% down$75.96$19.60
20244.3× 95.5% up$45.14$10.50
20232.2× 43.9% down$27.56$12.53
20223.9× 24.8% down$38.17$9.74
20215.2× 50.8% down$39.83$7.64
202010.6× 14.9% up$61.03$5.77
20199.2×—$48.03$5.22
2018——$34.32—
2017——$16.68—
2016——$10.91—
2015——$32.40—
201464.7× 931.6% up$51.77$0.80
20136.3×—$16.97$2.70
2012———$54.99
2011———$15.52

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

P/S ratio at health care companies of similar size

P/S ratio of PTC Therapeutics and comparable companies
CompanyP/S ratio
BillionToOne BLLN15.3×
Hims & Hers Health HIMS1.8×
PTC Therapeutics PTCT2.9×
Haemonetics HAE4.1×
Concentra Group Holdings Parent CON2.5×

Today's market value divided by revenue for the latest fiscal year. A company whose statements are in another currency than its shares is left out.

More on PTCT

PTC Therapeutics, figure by figure

PTC Therapeutics (PTCT) overview: price, valuation and scorecardAll health care companies by market value

PTC Therapeutics P/S ratio: questions and answers

What is PTC Therapeutics's P/S ratio?

PTC Therapeutics (PTCT) trades at 3.1× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 3.9×. That is 9.8% lower than the 4.3× of fiscal 2024.

Is PTC Therapeutics's P/S ratio high or low compared with its own history?

Today's P/S ratio is higher than at 11% of the 9 fiscal year-ends on record; their median is 5.2×.

What are the highest and lowest P/S ratio figures on record for PTC Therapeutics?

Across the 9 fiscal year-ends on record (2013–2025), the highest was 64.7× in fiscal 2014 and the lowest 2.2× in fiscal 2023.

How is PTC Therapeutics's P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “PTC Therapeutics (PTCT) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/PTCT/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.